# LivaNova PLC (LIVN) Stock Analysis: Exploring a 30% Upside Potential

- Link: https://www.directorstalkinterviews.com/livanova-plc-livn-stock-analysis-exploring-a-30-upside-potential/4121247333
- Published: 2026-03-31T10:08:34+01:00
- Author: Madison Wilson

LivaNova PLC (LIVN), a pioneering name in the healthcare sector, operates within
the medical devices industry and is headquartered in London, United Kingdom. With
a market capitalization of $3.35 billion, LivaNova is a prominent player in the 
global medical technology landscape. The company’s operations are split into two
main segments: Cardiopulmonary and Neuromodulation, addressing critical needs such
as heart-lung support and neuromodulation therapies for epilepsy and depression.

Currently trading at $61.27, LivaNova’s stock has experienced a slight dip of 0.01%
recently, yet it remains within a 52-week range of $33.85 to $71.00. The company’s
forward P/E ratio stands at a compelling 13.39, indicating a potentially undervalued
stock in relation to its expected earnings. Although specific valuation metrics 
like PEG and Price/Book ratios are unavailable, the forward P/E suggests that investors
might find value in LivaNova’s growth prospects.

The company’s revenue growth of 12.10% is a testament to its robust business model
and innovative product offerings. Despite reporting a negative EPS of -4.45 and 
a concerning Return on Equity of -19.24%, LivaNova’s strong free cash flow of over
$834 million provides a solid financial cushion, enabling continued investment in
R&D and potential strategic acquisitions.

Interestingly, LivaNova does not currently offer a dividend yield, aligning with
its strategy to reinvest earnings into growth opportunities rather than returning
capital to shareholders. The company’s payout ratio is at 0.00%, suggesting a focus
on long-term capital appreciation over immediate income.

Analyst sentiment towards LivaNova is predominantly positive, with 8 buy ratings,
3 hold ratings, and no sell ratings. The target price range for LIVN stock is set
between $67.00 and $90.00, with an average target of $79.91, offering a potential
upside of 30.42% from its current price. This bullish outlook reflects confidence
in LivaNova’s strategic direction and market potential.

From a technical perspective, LivaNova’s stock is trading below its 50-day moving
average of $64.82 but above its 200-day moving average of $56.48. The Relative Strength
Index (RSI) at 33.21 suggests that the stock is nearing oversold territory, which
might present an attractive entry point for value-focused investors. The MACD indicator
at -0.87, close to its signal line of -0.88, indicates a bearish trend, but the 
technicals could shift positively if sentiment improves.

LivaNova’s diversified portfolio, spanning critical medical areas such as cardiopulmonary
and neuromodulation, positions it well to capitalize on growing healthcare demands.
The company’s innovative thrust, particularly in developing solutions for drug-resistant
conditions, underscores its commitment to addressing unmet medical needs.

For investors seeking exposure to the dynamic healthcare sector, LivaNova presents
a unique opportunity. With a strategic focus on technological advancement and an
encouraging analyst consensus, LIVN could be well-positioned for future growth, 
making it a stock worth considering for those looking to capitalize on its potential
upside.

Share on: